Neoplastic meningitis

Katsuyuki Hotta, Mitsune Tanimoto

Research output: Contribution to journalArticlepeer-review


Neoplastic meningitis (NM) is a common problem in neuro-oncology. Notwithstanding its frequent focal signs and symptoms, NM is a disease affecting the entire neuraxis, and therefore its staging and treatment must include all cerebrospinal fluid (CSF) compartments. Diagnosis of NM is conducted by magnetic resonance imaging (MR-Gd) and pathological examination using CSF. Treatments of NM include involved-field radiotherapy of bulky or symptomatic disease sites, systemic chemotherapy, or intra-CSF drug therapy. At present, intra-CSF drug therapy is confined to three chemotherapeutic agents (i. e., methotrexate, cytosine arabinoside, and thio-TEPA) administered in a variety of schedules either by intralumbar or intraventricular delivery. Although treatment of NM is palliative with an expected median patient survival of 2 to 6 months, it often affords stabilization and protection from further neurologic deterioration in patients with NM. Recently, liposomal cytarabine has been developed and introduced in several clinical trials, demonstrating promising results.

Original languageEnglish
Pages (from-to)515-517
Number of pages3
JournalJapanese Journal of Cancer and Chemotherapy
Issue number4
Publication statusPublished - Apr 2011


  • Intrathecal chemotherapy
  • Neoplastic meningitis
  • Slowrelease formulation of cytarabine

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Neoplastic meningitis'. Together they form a unique fingerprint.

Cite this